Holen Sie sich die Stockscreener-App
194.82
6.98%
12.71
Vorhandelsmarkt:
195.82
1.00
+0.51%
Schlusskurs vom Vortag:
$182.11
Offen:
$180.6
24-Stunden-Volumen:
16.53M
Relative Volume:
1.03
Marktkapitalisierung:
$77.78B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-23.92
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
+23.25%
1M Leistung:
+40.27%
6M Leistung:
+279.47%
1J Leistung:
+652.78%
1-Tages-Spanne:
$180.39
$195.71
1-Wochen-Bereich:
$150.26
$195.71
52-Wochen-Spanne:
$22.28
$195.71
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna CEO’s Realistic Approach to Innovation - WSJ
Moderna, Inc. Stock Analysis: Momentum Builds Amid Overbought Signals - The Cryptonomist
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Moderna stock heads into the open after a 6.98 percent gain - AD HOC NEWS
Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24. - finance.yahoo.com
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better - Stocktwits
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
$Moderna (MRNA.US)$ thanks - Moomoo
Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak - finance.yahoo.com
From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done - finance.yahoo.com
Moderna Rises as Cancer-Vaccine Momentum and Pipeline Visibility Stay in Focus - quiverquant.com
Moderna Inc Stock (MRNA) Moved Up by 5.91% on Sep 24: What Investors Need To Know - TradingKey
Moderna's View of the Global Pharma Industry - WSJ
Top Biotech Stocks To Keep An Eye OnSeptember 24th - MarketBeat
A New Cancer Vaccine Shows Promise for Melanoma—Here’s What Doctors Know So Far - elle.com
Moderna stock trades below its 52-week high before cancer data - AD HOC NEWS
Dear Doctor: Should I hold off on my flu shot until I'm eligible for the new version? - syracuse.com
Biotech Stocks At 52-Week HighsTKNO, MRNA, ATRC, ILMN - RTTNews
Nykredit A S Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
Engineers Gate Manager LP Cuts Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna stock gains 4.5 percent ahead of the open - ad-hoc-news.de
Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines - Barron's
Moderna stock rises 5.6 percent at the close - AD HOC NEWS
Healthcare Stocks Fall -- Healthcare Roundup - marketscreener.com
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID - finance.yahoo.com
symbol__ Stock Quote Price and Forecast - CNN
MRNA: Broad mRNA platform advances, led by oncology and rare disease innovation, drive future growth - TradingView
Moderna Stock Forecast: MRNA Hits $187 as Melanoma Vaccine Fuels Rally - FXLeaders
Moderna’s mRNA flu shot hits the target - Science News
Moderna stock rises 5.6 percent on melanoma data - AD HOC NEWS
Moderna stock gains 5.6 percent ahead of the open - AD HOC NEWS
Moderna stock gains 5.6 percent as melanoma data approaches - AD HOC NEWS
Moderna (MRNA) Co Founder Joined An AI Drug Discovery Company - simplywall.st
Moderna (NASDAQ:MRNA) Trading Up 5.6%What's Next? - MarketBeat
Moderna, Inc.'s stock price soars to $182.56, marking a robust 5.56% increase: A lucrative investment opportunity - Smartkarma
Moderna stock gains 5.16 percent after the close - AD HOC NEWS
Moderna's Surge Faces Wall Street Skepticism as Analysts Question Cancer Vaccine Rally - finance.biggo.com
Was Moderna Stock's Cancer Vaccine Run Visible In Advance? - finance.yahoo.com
Was Moderna Stock’s Cancer Vaccine Run Visible In Advance? - trefis.com
Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis - TradingKey
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No." - The Globe and Mail
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up? - finance.yahoo.com
UBS reiterates Moderna stock rating ahead of melanoma data - Investing.com
How the Merck-Moderna mRNA melanoma vaccine is built per patient - qz.com
Top 3 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going - finance.yahoo.com
Moderna Says Sanofi Wants To 'Unjustly Profit' In Vax IP Suit - law360.com
Moderna (MRNA) Stock Trades Up, Here Is Why - Yahoo Finance
Stocks in Demand: MRNA and SAMAIDEN Lead Investor Attentions - Moomoo
Moderna, Inc.’s stock price skyrockets to $172.94, marking an impressive 12.27% surge - Smartkarma
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):